



DynamX Coronary Bioadaptor

Uniquely integrated elements designed to deliver
Triple Stage Therapy



DynamX restores pulsatility

At 12-months: DynamX bioadaptor uniquely uncaged
to deliver superior pulsatility and lumen area changes with every heartbeat vs DES¹




Findings from paired imaging analysis. Lumen area changes measured by stationary IVUS across at least 3 cardiac cycles (n=46 DynamX; n=46 DES). DES = drug-eluting stents. IVUS = intravascular ultrasound. ns = not significant.


1. Saito, S, et al. First randomised controlled trial comparing the sirolimus-eluting bioadaptor with the zotarolimus-eluting drug-eluting stent in patients with *de novo* coronary artery lesions: 12-month clinical and imaging data from the multi-centre, international, BIOADAPTOR-RCT. The Lancet Nov 2023; 1-13.

Vessel pulsatility restored with DynamX bioadaptor

Post Implant Pulsatility was Constrained in Both Arms
Post Implant Lumen Area Change





Pulsatility at 12 Months Restored in DynamX
12-Month Lumen Area Change



Saito, S, et al. First randomised controlled trial comparing the sirolimus-eluting bioadaptor with the zotarolimus-eluting drug-eluting stent in patients with *de novo* coronary artery lesions: 12-month clinical and imaging data from the multi-centre, international, BIOADAPTOR-RCT. The Lancet Nov 2023; 1-13.


Restores positive adaptive remodeling

A CORONARY VESSEL NATURALLY UNDERGOES POSITIVE ADAPTIVE REMODELING



DynamX restores positive adaptive remodeling

Significantly lower late lumen loss in overall cohort & subgroups especially in vessels and lesions at high risk of restenosis¹



1. Saito, S, et al. First randomised controlled trial comparing the sirolimus-eluting bioadaptor with the zotarolimus-eluting drug-eluting stent in patients with *de novo* coronary artery lesions: 12-month clinical and imaging data from the multi-centre, international, BIOADAPTOR-RCT. The Lancet Nov 2023; 1-13.

DynamX flow effect: Increase in blood flow with every heartbeat

PULSATILITY

7.5%

In-device % increase in lumen area:
2.7% (± 2.7) post-procedure and 7.5%
(± 4.6) at 12 months for Dynamx¹



BLOOD FLOW

16.7%

Blood flow increase per heartbeat:
6.5% (± 0.6) post-procedure and
16.7% (± 1.3) at 12 months for
Dynamx¹

Findings from paired imaging analysis. Lumen area changes measured by stationary IVUS across at least 3 cardiac cycles (n=46 DynamX; n=46 DES). DES = drug-eluting stents. IVUS = intravascular ultrasound. ns = not significant.

Saito, S, et al. First randomised controlled trial comparing the sirolimus-eluting bioadaptor with the zotarolimus-eluting drug-eluting stent in patients with *de novo* coronary artery lesions: 12-month clinical and imaging data from the multi-centre, international, BIOADAPTOR-RCT. The Lancet Nov 2023; 1-13.